Pulmonary Arterial Hypertension - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 214
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P22F8A1E6D7EN
Leaflet:

Download PDF Leaflet

Pulmonary Arterial Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
  • The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Pulmonary Arterial Hypertension Overview
Therapeutics Development
Pipeline Products for Pulmonary Arterial Hypertension - Overview
Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis
Pulmonary Arterial Hypertension - Therapeutics under Development by Companies
Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes
Pulmonary Arterial Hypertension - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pulmonary Arterial Hypertension - Products under Development by Companies
Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
Actelion Ltd
APT Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Ascendis Pharma A/S
AVEO Pharmaceuticals, Inc.
Bial - Portela & Ca, S.A.
Celsion Corporation
Celtaxsys, Inc.
Chugai Pharmaceutical Co., Ltd.
Complexa, Inc.
Eli Lilly and Company
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
HitGen LTD
Insmed Incorporated
INVENT Pharmaceuticals, Inc.
Johnson & Johnson
Kowa Company, Ltd.
Mast Therapeutics, Inc.
Mezzion Pharma Co. Ltd.
miRagen Therapeutics, Inc.
Morphogen-IX Limited
Nippon Kayaku Co., Ltd.
Nippon Shinyaku Co., Ltd.
Novartis AG
Peloton Therapeutics, Inc.
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proteo, Inc.
Pulmokine, Inc.
Reata Pharmaceuticals, Inc.
Respira Therapeutics, Inc.
Reviva Pharmaceuticals Inc.
Selten Pharma, Inc
Silence Therapeutics Plc
SteadyMed Therapeutics, Inc.
Suda Ltd
Toray Industries, Inc.
Pulmonary Arterial Hypertension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acebilustat - Drug Profile
Antibody for Pulmonary Arterial Hypertension - Drug Profile
Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile
APT-602 - Drug Profile
AV-353 - Drug Profile
bardoxolone methyl - Drug Profile
beraprost sodium ER - Drug Profile
beraprost sodium SR - Drug Profile
BIA-51058 - Drug Profile
BMP-10 - Drug Profile
BMP-9 - Drug Profile
CTX-3397 - Drug Profile
CXA-10 - Drug Profile
Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile
GMA-301 - Drug Profile
GMCT-01 - Drug Profile
GRMD-02 - Drug Profile
HGP-1207 - Drug Profile
INS-1009 - Drug Profile
INV-240 - Drug Profile
JNJ-26993135 - Drug Profile
KAR-5585 - Drug Profile
macitentan - Drug Profile
MFC-1040 - Drug Profile
MFC-2040 - Drug Profile
Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile
PB-1046 - Drug Profile
PB-1120 - Drug Profile
PF-543 - Drug Profile
pitavastatin NP - Drug Profile
PK-10453 - Drug Profile
PK-10571 - Drug Profile
PLX-PAD - Drug Profile
PT-2977 - Drug Profile
QCC-374 - Drug Profile
R-190 - Drug Profile
ralinepag - Drug Profile
RP-5063 - Drug Profile
RT-234 - Drug Profile
selexipag - Drug Profile
selonsertib - Drug Profile
sirolimus albumin-bound - Drug Profile
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile
Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile
sodium nitrite - Drug Profile
SPI-054 - Drug Profile
SPI-183 - Drug Profile
SUD-004 - Drug Profile
Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile
tacrolimus - Drug Profile
tadalafil - Drug Profile
tiprelestat - Drug Profile
tocilizumab - Drug Profile
TR-422 - Drug Profile
treprostinil - Drug Profile
treprostinil diolamine - Drug Profile
ubenimex - Drug Profile
udenafil - Drug Profile
Pulmonary Arterial Hypertension - Dormant Projects
Pulmonary Arterial Hypertension - Discontinued Products
Pulmonary Arterial Hypertension - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 210

LIST OF TABLES

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2016
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016
Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Complexa, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H2 2016
Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Kowa Company, Ltd., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Limited, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Pulmokine, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Selten Pharma, Inc, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2016
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2016
Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pulmonary Arterial Hypertension - Dormant Projects, H2 2016
Pulmonary Arterial Hypertension - Dormant Projects (Contd..1), H2 2016
Pulmonary Arterial Hypertension - Dormant Projects (Contd..2), H2 2016
Pulmonary Arterial Hypertension - Dormant Projects (Contd..3), H2 2016
Pulmonary Arterial Hypertension - Discontinued Products, H2 2016 202

LIST OF FIGURES

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Pulmonary Arterial Hypertension - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: